FACTOR XIA-INHIBITING PYRIDOBENZAZEPINE AND PYRIDOBENZAZOCINE DERIVATIVES
申请人:BAYER PHARMA AKTIENGESELLSCHAFT
公开号:US20170275282A1
公开(公告)日:2017-09-28
The invention relates to substituted pyridobenzazepine and pyridobenzazocine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.
A Reagent-Controlled Phospha-Michael Addition Reaction of Nitroalkenes with Bifunctional N-Heterocyclic Phosphine (NHP)-Thioureas
作者:Hai Huang、Jake Palmas、Jun Yong Kang
DOI:10.1021/acs.joc.6b02490
日期:2016.12.2
phospha-Michael addition reaction of nitroalkenes to afford diversely substituted β-nitrodiazaphosphonates. This transformation takes place at room temperature under catalyst-free conditions and exhibits broad functionalgroup tolerance. The key to success in catalyst, additive-free reaction conditions is the suitable hydrogen-bond activation of the nitro group by a Brønsted acid (thiourea), which
Compounds of Formula (I): in which A
1
, A
2
, W, L, G, R
7a
, R
7b
, R
8
, R
9
and R
10
have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.
Compounds of Formula (I): in which A1, A2, W, L, G, R7a, R7b, R8, R9 and R10 have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.